Paper42730438
Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study.
Sawaf B and 10 others. Crohns Colitis 360, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study. Papers, record 42730438. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42730438
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40260307 | Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients. | Crohns Colitis 360 | 2025 | https://conductscience.org/library/papers/40260307 | PubMed |
| 2 | 36975373 | Significant Racial and Ethnic Disparities Exist in Health Care Utilization in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. | Inflamm Bowel Dis | 2024 | https://conductscience.org/library/papers/36975373 | PubMed |
| 3 | 33935763 | Novel and Emerging Therapies for Inflammatory Bowel Disease. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33935763 | PubMed |
| 4 | 35644155 | Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. | Lancet | 2022 | https://conductscience.org/library/papers/35644155 | PubMed |
| 5 | 31944255 | Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus. | Inflamm Bowel Dis | 2020 | https://conductscience.org/library/papers/31944255 | PubMed |
| 6 | 23964933 | Vedolizumab as induction and maintenance therapy for Crohn's disease. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23964933 | PubMed |
| 7 | 35644154 | Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. | Lancet | 2022 | https://conductscience.org/library/papers/35644154 | PubMed |
| 8 | 30097359 | Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. | Lancet | 2018 | https://conductscience.org/library/papers/30097359 | PubMed |
| 9 | 36058820 | Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis. | Dig Liver Dis | 2023 | https://conductscience.org/library/papers/36058820 | PubMed |
| 10 | 29507339 | Socioeconomic Status and Race are both Independently associated with Increased Hospitalization Rate among Crohn's Disease Patients. | Sci Rep | 2018 | https://conductscience.org/library/papers/29507339 | PubMed |
| 11 | 33512666 | Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial. | Dermatol Ther (Heidelb) | 2021 | https://conductscience.org/library/papers/33512666 | PubMed |
| 12 | 23075178 | Ustekinumab induction and maintenance therapy in refractory Crohn's disease. | N Engl J Med | 2012 | https://conductscience.org/library/papers/23075178 | PubMed |
| 13 | 32617771 | Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications. | Dig Dis Sci | 2021 | https://conductscience.org/library/papers/32617771 | PubMed |
| 14 | 29050646 | Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. | Lancet | 2017 | https://conductscience.org/library/papers/29050646 | PubMed |
| 15 | 28411872 | Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. | Lancet | 2017 | https://conductscience.org/library/papers/28411872 | PubMed |
| 16 | 27959607 | Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959607 | PubMed |
| 17 | 25116048 | Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study. | PLoS One | 2014 | https://conductscience.org/library/papers/25116048 | PubMed |
| 18 | 35573757 | Iron Deficiency Anemia: An Overlooked Complication of Crohn's Disease. | J Hematol | 2022 | https://conductscience.org/library/papers/35573757 | PubMed |
| 19 | 28423301 | Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28423301 | PubMed |
| 20 | 39018531 | Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39018531 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42730438
GET https://conductscience.org/api/papers/v1/42730438/references?page=2